Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
706 JPY | -0.56% | +1.15% | +24.51% |
Income Statement Evolution (Annual data)
Fiscal Period: |
---|
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 Q3 | 2021 Q1 | 2021 Q3 | 2022 Q1 | 2022 Q3 | 2023 Q1 |
---|---|---|---|---|---|---|
Net sales 1 | 71 | 62 | 125 | 193 | 358 | 35 |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -507 | -349 | -330 | -384 | -279 | -325 |
Operating Margin | -714.08% | -562.9% | -264% | -198.96% | -77.93% | -928.57% |
Earnings before Tax (EBT) 1 | -880 | -349 | -327 | -328 | -264 | -322 |
Net income 1 | -881 | -350 | -329 | -328 | -265 | -323 |
Net margin | -1,240.85% | -564.52% | -263.2% | -169.95% | -74.02% | -922.86% |
EPS 2 | -61.21 | -22.36 | -18.97 | -18.98 | -15.28 | -18.69 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 11/6/20 | 5/7/21 | 11/5/21 | 5/13/22 | 11/4/22 | 5/12/23 |
Balance Sheet Analysis
Fiscal Period: |
---|
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+24.51% | 96.38M | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- 4588 Stock
- Financials Oncolys BioPharma Inc.